Introduction
Atherosclerotic lesions of the extracranial part of carotid arteries are one of the most common causes of stroke. The relationship between carotid artery occlusive disease and neurologic function has been recognized for more than, 2000 years. According to Rufus of Ephesus (about 100 AD), the term carotid was derived from the Greek word κάρος (karos), meaning "to stun, to fall into deep sleep". The reason for naming the artery was that compressing it causes the loss of consciousness -"deep sleep" 1 . Hippocrates "apoplexy" in 400 BC was the first written trace of human attempt to portray conditions that we know today as transient ischemic attack (TIA) or reversible ischemic neurologic deficit 1 . Awareness of carotid arteries disease and surgical attempts to repair them led to the first successful carotid endarterectomy (CEA), performed by Michael DeBakey in 1953 2 . Since then, carotid surgery has developed a lot, so today we have various techniques to detect and treat diseased carotid arteries 1 .
Diagnostic improvement
Preoperative imaging plays irreplaceable role in successful treatment of not just carotid arteries, but any organ, as well.
Carotid duplex scan (CDS) represents the first line in the diagnostics of carotid disease. This technology, which combines the acquisition of anatomic and blood flow information, was developed in the 1970s 3 . Commercial duplex scanners became available by the 1980s, and the clinical use of CDS rapidly expanded in the past twenty years 4 . Modern CDS systems provided high-resolution Bmode ultrasound imaging of tissue and vessel anatomy, including 3D vessel reconstruction and evaluation of atherosclerotic plaque morphology, with detailed assessment of blood flow characteristics 4 . CDS is noninvasive and cost-effective and thus suitable for serial examination because it also reveals natural history of disease, including progression, regression, and response to intervention. In many patients, duplex testing can establish the definitive diagnosis the basis on which CEA or angioplasty can be performed 4 . However, the reliability of CDS depends on the expertise of the examiner and the interpreting physician.
When introduced in 1971, computed tomography (CT) scan brought a great improvement in the diagnostics 5 . Technological development led to the invention of 4-slice in 1998 and 16-slice multidetector CT (MDCT) scanner in 2002 5, 6 . Later, the 256-slice MDCT provided ability to generate ''real time'' 3D images (Figure 1 ), for about the same amount of radiation as previous MDCT scanners 5 . Also, increasing use of MDCT angiography provided better visualization of the cerebral arteries, leading to an unexpected more frequent detection of unruptured intracranial aneurysms (UIAs) 7 . Dual source MDCT scanners, developed in 2006, could precisely evaluate plaque distribution in the arteries, as well as they could make difference between calcified and lipidrich plaques (Figure 2 ), which is of great importance in preoperative planning 5, 8, 9 . Because scanning with MDCT is done quickly, less contrast material can be administered at a faster rate, improving visibility of arteries 5, 6 . Rapid patient throughput reduces breath-holding time and received amount of radiation, which provides greater comfort for patients 5, 6 . It also raises department productivity and saves money 6 . Apart from the hardware type of a scanner, postprocessing software and image management tools continue to evolve and warrants upgrade in a timely fashion.
The future of CT imaging lies in the fusion imaging technique. As a technology which enables synthesis of two dependent imaging modalities, it provides image with greater information. Positron emission tomography (PET)-CT fusion is the most relevant in the current clinical practice 5 .
Eversion carotid endarterectomy
Although first described by DeBakey in 1959 10 , the modern technique of eversion CEA (ECEA) was introduced in the early 1970s 11 . However, its use became more popular about twenty years later 12 . At the end of the 20th and the beginning of the 21st century, surgeons worldwide began to report better outcomes following ECEA compared to the conventional technique (Table 1) .
The majority of studies showed lower incidence of early postoperative death and neurological complications (seven days after surgery) 1−14, 16−25 in group treated with eversion technique. Also, incidence of late restenosis (follow-up period 36.4 ± 15.8 months 24 ) was much lower in patients treated with ECEA versus conventional CEA (Table 2 ).
In addition, Gao et al. 28 documented surprisingly lower incidence of postoperative microembolic events in ECEA, compared to the standard endarterectomy.
One of the world's largest single-center series of ECEA, by Radak et al. 12 , compared outcomes in patients operated on between 1991 and 1997 with those operated on in 1998−2004 period of time. The total mortality and morbidity rates and early postoperative complications were lower in the latter group. The clamping time was shorter, as well as was duration of hospital stay. At follow-up, rate of restenosis > 50% did not differ between the groups, but the incidence of < 50% restenosis was higher in the earlier group.
Improved surgical skills, shorter clamping time and better medication therapy led to preferable outcomes in patients operated on between 1998 and 2004 12, 25 . As a technique, ECEA offers lower restenosis rates and CCEA -conventional carotid endarterectomy; ECEA -eversion carotid endarterectomy. 16, 25 . Also, ECEA has been identified as an independent factor contributing to a better outcome following surgery 29 . Still, there are certain relative contraindications to ECEA: restenosis after previous CEA, carotid stenosis due to radiation, ipsilateral surgical intervention in the past and lesions above second cervical vertebra 24, 30−33 . Therefore, alternative techniques have evolved.
Carotid artery stenting
The endovascular era began, by seeking less invasive alternative to open surgery. First successful results of percutaneous transluminal angioplasty (PTA) of carotid arteries were reported by Matthias 34 in 1977 and Kerber et al. 35 in 1980. Balloon-expandable stents were first deployed in 1989, with improving of stent material and technique over years 36 . Despite the early enthusiasm, the high likelihood of embolic stroke during carotid artery stenting (CAS) remained a major concern. The development of embolic protection devices (EPDs) in the 1990s has lowered the incidence of microembolization and consequent neurologic deficit 24, 36−38 . From the beginning of the modern endovascular period, the procedure has been largely scrutinized. Four main inno- 36 . However, the question of CAS as an "equivalent" therapeutic option to CEA still remained. Five large randomized clinical trials were conducted seeking for answers to this dilemma (Table 3) .
Except stent protected angioplasty vs carotid endarterectomy (SPACE) and international carotid stenting study (ICSS) (27% and 72%, respectively), in other trials EPDs were used in > 90% of cases. Asymptomatic patients were enrolled in carotid revascularization endorterectomy vs stenting trial (CREST) and stenting and angioplasty unith protection in patients at high risk for endarterectomy (SAP-PHIRE) trial.
The results implied to a higher perioperative stroke risk with CAS compared with CEA when it is performed in unselected patients with symptomatic or asymptomatic carotid stenosis. The association between older age and increased risk of adverse events after CAS, was reported in CREST, ICSS and SPACE trial 43−47 . The low absolute risk of recurrent stroke in CREST suggests that both CAS and CEA are clinically durable 47 .
CREST -carotid revascularization endarterectomy vs stenting trial; EVA-3S -endarterectomy vs angioplasty in patients with symptomatic severe carotid stenosis; ICSS -international carotid stenting study; MI -myocardial infarction, n -number of patients; SAPPHIRE -stenting and angioplasty with protection in patients at high risk for endarterectomy; SPACE -stent-protected angioplasty vs carotid endarterectomy; y -year.
The risk of periprocedural myocardial infarction after CAS was reported with rates about half as those of CEA: 1.1% vs 2.3% in CREST, 0.4% vs 0.6% in ICSS and 0.4% vs 0.8% in endarterectomy vs angioplasty in patients with symptomatic carotid stenosis (EVA-3S) trial 41, 46, 47 . CAS should not be considered as an therapeutic option in patients with severe peripheral artery stenosis, aortic arch anomalies, carotid artery kinking/coiling and aneurysm, preocclusive lesions of the internal carotid artery (ICA), carotid stenosis longer than 2 cm, calcified, ulcerated or highly vulnerable carotid plaque and chronic renal insufficiency 24 . In such cases, open surgery remains the gold standard.
Currently, data suggest that with a careful patient and operator selection and improved technology, CAS may be considered as an alternative to CEA 36, 39−47 .
Hybrid procedures
Significant atherosclerotic lesions involving carotid bifurcation and the proximal ipsilateral common carotid artery (CCA) or the innominate artery (IA) are uncommon, with the reported incidence of approximately 4.8% 48 . However, their treatment remains a great challenge. Standard CEA exposure does not allow repair of the proximal IA or CCA; it could be approached through a median sternotomy, occasionally requiring cardiopulmonary bypass 49 . On the other side, the access to skull base-level ICA stenosis mandates mandibular subluxation 50 . These procedures are associated with a prolonged operative time, increased blood loss and increased morbidity/mortality incidence 51 . In 1996, Diethrich et al. 52 described a new, hybrid technique for simultaneous treatment of carotid bifurcation and proximal lesions. This procedure consisted of surgical exposure of carotid bifurcation, retrograde stenting of the proximal CCA or IA lesions, followed by CEA.
A meta-analysis by Sfyroeras et al. 53 reported a 30-day periprocedural stroke and mortality rates of 1.5% and 0.7%, respectively. During follow-up, the incidence of restenosis in patients treated with stenting was 3.7% vs 14% in patients that received simple balloon angioplasty, further signalizing that proximal lesions should be solved with stent implantation. In order to assure better outcomes in patients that did not receive antiplatelet therapy, an increased dose of clopidogrel (450 mg) should be delivered immediately before the intervention 54 . Comparing mortality rates of hybrid procedures and open surgical approach (0.7% vs 0.5%−18.7%), stands clear that the hybrid technique made significant breakthrough in treatment of simultaneous lesions 53 . The results of hybrid procedures label that CEA and CAS should not be considered as competitive, but complementary techniques.
Local anesthesia
CEA can be performed using general anesthesia (GA) and/or local anesthesia (LA). LA comprises deep and superficial cervical block. Cervical block anesthesia (CBA) has evolved over the last 15 years with new techniques, novel methods of locating the cervical plexus and new drugs 55−57 .
Using CBA, neurological function is easily assessed during carotid crossclamping, with predictable haemodynamic control. In patients with significant cardiopulmonary comorbidities or in which GA is contraindicated, LA represents a safe and effective option. Disadvantages of LA include risk of seizure or allergic reaction, discomfort for some patients and anxiety for the operating surgeon 58 . The general anaesthesia vs local anesthesia for carotid surgery (GALA) trial was designed to compare outcomes in patients operated on under GA or LA. The results showed no significant difference in the incidence of stroke, myocardial infarction or death at a 30-day follow up. Adverse cardiovascular events were reported in 4.8% of patients who underwent CEA under GA and 4.5% of patients who underwent CEA under LA. Also, there was no difference in hospital length of stay between the groups 59 . Since the GALA trial, several other studies have also reported subtle differences between GA and LA 55 . Referring to the results of these reports, we can say that the efficacy of vascular team looking after the patient is more important than the choice of anesthetic technique itself. Since no data showed predominance of GA or LA, selection of suitable anesthetic method remains to be discussed between the patient, his surgeon and anesthesiologist.
Best medical treatment
The invention of new, potent drugs, led to an idea of creating a novel therapeutic modality for carotid arteries disease, named the best medical treatment (BMT).
One of the most significant improvements has been the aggressive use of antiplatelet therapy, and early studies reported up to 25% reduction in overall stroke rates among patients undergoing CEA 58 . When clopidogrel bisulfate was approved by the Food and Drug Administration (FDA) in 1998 60 , a new chapter in antiplatelet therapy has been opened.
Addition of a single 75 mg dose of clopidogrel to a regular 75 mg dose of acetylsalicylic acid (ASA), administered the night before CEA, was associated with a significant reduction in postoperative neurological events, without any increase in hemorrhagic complications 61 . A study of Sharpe et al. 62 showed a lower incidence of postoperative microembolisation in patients receiving dual therapy, compared to patients receiving only ASA. Also, the need of adjuvant dextran therapy was reduced.
The utility of dual antiplatelet therapy use after CAS has been observed in the management of atherothrombosis with clopidogrel in high risk patients (MATCH) with recent transient ischemic attack or ischemic stroke and the clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (CHARISMA) trials 63−65 . The benefit of combination therapy was found to be significant in patients with symptomatic carotid disease; conversely, the related risk of bleeding obviated the benefits of treatment in patients with low risk of postprocedural neurologic complications 64, 65 . A recent study showed that the use of ASA and clopidogrel 4−6 weeks after CAS is suffici-ent to decrease the risk of ischemic stroke, composite vascular events or death 66 .
Recently, there has been an increasing argument to favor BMT as stand-alone treatment in all neurologically asymptomatic individuals, regardless of the degree of carotid stenosis 78 . This argument deserved serious critical analysis, because the majority of carotid interventions currently performed are in asymptomatic patients. In an effort to address the question of BMT in patients with confirmed carotid disease, Abbott et al. 79 performed metaanalyses of 11 trials that included 3724 patients with ≥ 50% carotid stenosis. Comparing their results with the results from endarterectomy for asymptomatic carotid artery stenosis (ACAS) trial, they determined that the contemporary risk of ipsilateral stroke and/or TIA did not differ, and possibly were better than the results reported for ACAS in 1995.
Apart from antiplatelet agents, lipid lowering drugs have significant role in prevention of major cardiovascular events. Since lovastatin had been commercialized in September 1987, 6 statins, including 2 semi-synthetic statins (simvastatin, pravastatin) and 4 synthetic statins (fluvastatin, atorvastatin, rosuvastatin, pitavastatin) have been introduced 67−69 . Statins have both lipid-lowering and antiinflammatory effects, and have been shown to reduce risk of neurologic events in symptomatic patients and in patients after CEA or CAS 70−72 . Furthermore, it appears that the stroke prevention benefits of statins are related to their pleiotropic effects rather than their cholesterol lowering effects 58 . Numerous trials and meta-analyses since the mid1990s, revealed a strong correlation of statin use and reduced stroke risk 58, 73−75 . In a recent series of 1,566 patients who underwent CEA, at a 30-day follow-up, statins were found to be associated with a reduced incidence of death (0.3% vs 2.1%), stroke (1.2% vs 4.5%) and TIA (1.5% vs 3.6%). A fivefold lower risk of death and a threefold lower risk of stroke was found in statin users group 76 . In a single-center experience, the incidence of cardiovascular events after CAS was 4% in statin users vs 15% in nonusers 77 . Another large series showed 1.5% vs 4% 30-day stroke/death rates for users and non-users 72 
.
The latest data, which provides the most contemporary comparison of BMT alone to BMT plus CEA or CAS, indicate that CEA followed by medical therapy represents the best modality in reduction of cardiovascular events.
Conclusion
Overviewing the last 20 years, we stepped forward in understanding, diagnosing and treating carotid arteries disease. More sophisticated preoperative imaging, improved surgical skills, development of new stent materials and techniques and new medication therapy led to better outcome following carotid arteries treatment. Yet, there is a long way to go in order to reduce incidence of peri-and postoperative adverse effects, especially in high risk patients and the elderly population. The saga continues...
In addition, according to multi-center experience, dual antiplatelet therapy and statins with angiotensin-converting enzyme (ACE) inhibitor or beta blocker after CEA or CAS, resulted in a lower incidence of restenosis and adverse postoperative effects (Table 4) 12, 36, 58, 76,78 . 
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